The Expanding Armamentarium for EGFR-Mutated Metastatic NSCLC
Clinical Trial Updates
•
1h 3m
Explore the expanding treatment options for EGFR mutated metastatic non-small cell lung cancer. Key topics include the role of biomarkers in treatment decisions, FDA-approved targeted therapies, and the necessity of comprehensive testing. A case study illustrates the diagnostic process leading to the identification of an EGFR Exon 19 deletion. The session emphasizes the importance of tailored treatment approaches and collaboration among healthcare professionals to improve patient outcomes.
Up Next in Clinical Trial Updates
-
ARC TALKS Webinar: Clinical Trial Upd...
The video is a webinar titled “ARC TALKS Webinar: Clinical Trial Updates for the ATTR Community,” presented by Kristen Hsu, ARC’s Executive Director of Research. The presentation is designed to update the ATTR amyloidosis community on the evolving clinical trial landscape for treatments targeting...
